表紙
市場調査レポート

PharmaPoint:B型肝炎ウイルス(HBV)予防ワクチン−−日本での医薬品の予測と市場分析

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 298834
出版日 ページ情報 英文 89 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
PharmaPoint:B型肝炎ウイルス(HBV)予防ワクチン−−日本での医薬品の予測と市場分析 PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022
出版日: 2014年01月31日 ページ情報: 英文 89 Pages
概要

全世界で20億人の人々がB型肝炎ウイルス(HBV)に感染しており、毎年60万人がB型肝炎関連の肝疾患で死亡しています。混合HBsAgワクチンの登場以来20年間で疾患負荷は大幅に軽減されましたが、成人へのワクチン摂取と有効性(特にニッチな疾患の場合)についてはまだ疑問が残っています。今後は、高リスク成人患者に対する高いセロコンバージョン率の達成や、各国ごとの政策的取り組みが、市場成長を促進していくものと思われます。しかし日本の場合、定期的な予防接種プログラムがまだ無く、また成人のリスク集団に対する予防接種も実施されていません。日本政府はワクチン接種に積極的ですが、HBV予防ワクチン接種率が近年中に上昇する見込みは少なく、それが市場成長の制約要因となっています。

当レポートでは、日本におけるB型肝炎ウイルス(HBV)予防ワクチンに関する最新の研究・開発状況と、関連市場の将来展望とを分析し、疾患の概要や治療法、市場機会とアンメットニーズ、市場規模の動向(今後10年間分)、上市済みの主なワクチンのプロファイル、日本市場の現状と今後の方向性などの情報を盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 概要
  • 病因と病態
    • 病因
    • 病態
  • 症状
  • 予後

第4章 ワクチンの摂取勧告と摂取率

  • 概要
  • 日本
    • 予防摂取の勧告と政策
    • 摂取率
    • 臨床診療

第5章 競争環境

  • 概要
  • 競合企業の戦略的評価
  • 製品のプロファイル:単価ワクチン
    • Recombivax HB
    • Bimmugen
  • 製品のプロファイル:混合ワクチン

第6章 市場機会とアンメットニーズ

  • 概要
  • ワクチンの免疫原性の増大
    • アンメットニーズ
    • ギャップの分析
    • 市場機会
  • ワクチン接種率の上昇
  • 患者の意識の高まり
  • 医師教育の改善
  • 費用対効果の高いワクチン

第7章 市場の見通し

  • 日本
    • 市場予測
    • 市場促進・阻害要因

第8章 付録

図表一覧

目次
Product Code: GDHC216CFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Similar to the situation in the UK, sales in the Japanese market are severely constrained by the absence of a routine HBV immunization program. Furthermore, Japan also does not target adult risk groups for HBV immunization, an approach that is unique among the eight markets discussed in this report. While Japanese policymakers have hinted at a more pro-vaccine stance, GlobalData does not expect HBV immunization recommendations to be expanded in Japan during the forecast period, which poses a serious barrier to market growth.

Scope

  • Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Hepatitis B disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Japan

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview
  • 4.2. Japan
    • 4.2.1. Immunization Recommendations and Policies
    • 4.2.2. Vaccination Coverage
    • 4.2.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Monovalent Vaccines
    • 5.3.1. Recombivax HB
    • 5.3.2. Bimmugen
  • 5.4. Product Profiles - Combination Vaccines

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Increased Vaccine Immunogenicity
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Increased Vaccination Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Patient Awareness
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. More Cost-Effective Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Market Outlook

  • 7.1. Japan
    • 7.1.1. Forecast
    • 7.1.2. Drivers and Barriers

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Methodology
  • 8.4. Forecasting Methodology
    • 8.4.1. Patient Populations Targeted for Vaccination
    • 8.4.2. Vaccination Coverage Rates
    • 8.4.3. Vaccinated Patients
    • 8.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 8.4.5. Vaccines Included
    • 8.4.6. Key Launch Dates
    • 8.4.7. General Pricing Assumptions
    • 8.4.8. Individual Vaccine Assumptions
  • 8.5. Physicians and Specialists Included in this Study
    • 8.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 8.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 8.6. About the Authors
    • 8.6.1. Analyst
    • 8.6.2. Therapy Area Director
    • 8.6.3. Global Head of Healthcare
  • 8.7. About GlobalData
  • 8.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Product Profile - Recombivax HB
  • Table 9: Immunogenicity Profile - Recombivax HB
  • Table 10: Safety Profile - Recombivax HB
  • Table 11: Recombivax HB SWOT Analysis, 2014
  • Table 12: Product Profile - Bimmugen
  • Table 13: Bimmugen SWOT Analysis, 2014
  • Table 14: Unmet Need and Opportunity in Prophylactic HBV Vaccines
  • Table 15: Sales Forecasts ($) for HBV Vaccines in Japan, 2012-2022
  • Table 16: Japan HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 17: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, Japan
  • Table 18: Key Launch Dates
  • Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, Japan

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
  • Figure 2: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Japan, 2014
  • Figure 3: Sales for HBV Vaccines in Japan, 2012-2022
Back to Top